Revenio Group Oyj

Major Shareholding Notification • May 22, 2015

Disclosure 324691

Revenio Group Oyj - Major shareholder announcements

Revenio Group Corporation: Notice pursuant to section 5, chapter 9 of the Securities Market Act

Revenio Group Corporation, Stock Exchange Release, May 22, 2015 at 12:00 NOTICE PURSUANT TO SECTION 5, CHAPTER 9 OF THE SECURITIES MARKET ACT Revenio Group Corporation has today received a notification of change in holdings in accordance with Chapter 9, Section 5 of the Securities Markets Act that Evli Pankki Oyj's share of the total number of shares and voting rights in Revenio Group Corporation has increased to more than one twentieth (1/20). Evli Pankki Oyj now holds 445,786 shares in Revenio Group Corporation, which is 5.62 percent of the company's shares and voting rights. The total number of Revenio Group Corporation's shares recorded in the trade register is 7,933,078. Olli-Pekka Salovaara President and CEO For further information, please contact: President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520 olli-pekka.salovaara@revenio.fi www.revenio.fi DISTRIBUTION: NASDAQ OMX Helsinki Financial Supervisory Authority (FIN-FSA) Principal media www.revenio.fi The Revenio Group in brief Revenio is a Finnish health tech group whose core business is in tonometers. The Revenio Health Tech segment comprises the business operations of Icare Finland Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis screening and monitoring. The common denominators of Revenio's business operations include screening, follow-up and the global need to make cost savings in health care via preventive measures. Revenio seeks vigorous growth in health technology, both organically and through acquisitions and mergers. Revenio aims at developing even more efficient and easily adopted methods for the early-stage detection of diseases with significance for public health. The focus of Revenio's screening technology lies on the early detection of glaucoma, osteoporosis, skin cancer and asthma, and the monitoring of these during the treatment process. In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group Corporation is listed on NASDAQ OMX Helsinki. [HUG#1923451]